Bionic Eye Approved—Seniors Reads Again

Woman holding chocolate bar over one eye against teal background — Photo: Dean Drobot / Shutterstock

A rice-sized eye chip and a pair of smart glasses are giving legally blind seniors the ability to read again.

Story Snapshot

Europe approved the PRIMA retinal implant, the first eye prosthesis to restore functional central vision lost to age-related macular degeneration.
In trials, most patients who were legally blind in the center of their vision could read letters, words, and numbers again.
The implant does not fix the eye back to normal, but it creates a new “digital” central vision that works with the brain.
This technology opens a new front in the fight against age-related blindness and raises sharp questions about access and expectations.

A bionic eye for age-related blindness moves from lab to clinic

European regulators have cleared a tiny retinal implant called PRIMA for commercial use, making it the first implantable device approved to restore central vision in people who lost it to age-related macular degeneration. The device will be sold across thirty European countries and first used in paying patients in Germany. Doctors will now move from carefully controlled trials into real-world practice with seniors who have few other options.

Age-related macular degeneration destroys the light-sensing cells in the center of the retina, which blocks the sharp vision used for reading faces, books, and road signs. Standard treatments can slow some forms but advanced dry macular degeneration with geographic atrophy leaves patients legally blind in the center of their sight. PRIMA targets this group, people whose central vision is gone and for whom medicine has offered almost nothing besides low-vision aids.

How the PRIMA system turns light into usable sight

Surgeons place a two-millimeter photovoltaic chip under the damaged central retina. Patients wear special glasses that capture images, boost contrast, and project patterns of infrared light onto the implant. Each pixel on the chip turns that light into tiny electrical pulses that stimulate surviving retinal neurons. Those neurons send signals along the optic nerve to the brain, which learns to treat the new input as central vision, much like a hearing aid for the eye.

Unlike older bulky retinal devices, PRIMA is wireless and uses natural eye movements. Patients look where they want to see, and the glasses feed processed images onto the chip. The system can add zoom and higher contrast, which is important because the artificial vision is lower resolution than a healthy eye. In trials, zoom helped some participants reach reading acuity close to 20/42, far better than legal blindness and enough for many daily tasks.

What the trials really showed patients could do

In the pivotal European PRIMAvera trial, 38 patients with profound central vision loss were implanted and followed for at least one year. Roughly four out of five gained clinically meaningful visual acuity, defined as at least two extra lines on a standard eye chart. On average, patients improved by about five lines, and one patient improved by twelve lines, a massive jump from near darkness to practical reading.

The headline result matters even more: over 80 percent of treated patients reported that they could read letters, numbers, and words using prosthetic central vision. Many had been unable to read at all before. One analysis found a mean gain of 25.5 letters on the ETDRS chart, more than five lines, with no loss in their remaining natural peripheral sight. This combination—reading again while keeping side vision—is why ophthalmologists view the device as a major advance.

How good is this “restored” vision in everyday life?

The new sight is still far from normal human central vision. Detailed follow-up work showed typical prosthetic acuity around 20/400 to 20/500, depending on pixel size and test method. That level meets the definition of legal blindness. Yet for someone who previously saw almost nothing in the center, being able to make out large letters, find doorways, or see the outline of a loved one’s face can shift daily life from dependence toward more independence.

Science Corp's PRIMA retinal implant just earned a CE mark: the first treatment shown to restore functional central vision in geographic atrophy. In the NEJM trial, 84% of patients could read again. Founded by Duke alum Max Hodak. pic.twitter.com/vFiG7abwOO

— Duke Capital Partners (@DukeCapPartners) July 27, 2026

Real-world reports showed that quality-of-life gains varied widely. Some patients used the system to read books and signs with digital zoom; others saw less dramatic change, limited by other eye disease or difficulty learning to interpret the new signals. That spread of outcomes is common in early brain-computer interface devices. From a conservative, common-sense view, the key is honest messaging: this is powerful assistive vision, not a magic return to perfect sight for every senior.

Risks, limits, and the path to wider adoption

Like any eye surgery, PRIMA implantation carries risk. In the clinical trial, most serious side effects occurred in the first two months and nearly all resolved within that period. The chip was stable under the retina for years, and importantly, average natural peripheral vision did not decline. United States regulators have allowed a feasibility study to begin, focused on both safety and restoration of visual perception over three years of follow-up.

Access and cost will drive the next phase of debate. Europe’s approval opens the door, but implants, surgery, and follow-up training will not be cheap. As with cochlear implants for hearing, society will need to decide how widely it supports high-tech help for age-related disability. From a liberty-oriented standpoint, giving seniors tools to stay independent and engaged aligns well with valuing personal responsibility—so long as promises match what the data actually show and families understand the trade-offs.